- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist exhibited
Northland Capital Markets analyst Michael Latimore initiates coverage on Crexendo (NASDAQ:CXDO) with a Outperform rating and announces Price Target of $4.